• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝炎患者作为尸体肝移植的主要适应证时,肝细胞癌和术后并发症的发生率较高。

High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation.

作者信息

Kern Barbara, Feurstein Benedikt, Fritz Josef, Fabritius Cornelia, Sucher Robert, Graziadei Ivo, Bale Reto, Tilg Herbert, Zoller Heinz, Newsome Philip, Eschertzhuber Stephan, Margreiter Raimund, Öfner Dietmar, Schneeberger Stefan

机构信息

Departments of Visceral, Transplantation and Thoracic Surgery.

Department of Surgery, Campus Charité Mitte and Campus Virchow Klinikum, Charité - Universitaetsmedizin Berlin, Berlin.

出版信息

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):205-210. doi: 10.1097/MEG.0000000000001270.

DOI:10.1097/MEG.0000000000001270
PMID:30320609
Abstract

BACKGROUND AND AIMS

Nonalcoholic steatohepatitis (NASH) is an increasingly prevalent indication for liver transplantation (LT) across the world. The relative outcomes following transplantation are poorly described in this cohort. We aimed to analyze the incidence and outcome of LT for NASH as compared with other indications.

PATIENTS AND METHODS

This is a retrospective analysis of 513 patients who underwent deceased-donor, adult LT between 2002 and 2012 as recorded at the Medical University of Innsbruck, Austria.

RESULTS

The prevalence of NASH cirrhosis as indication for liver transplantation was 12.7% (65/513). Patient survival in patients with NASH was comparable to other indications, including alcohol-induced liver steatosis (ALD) and hepatitis C virus (HCV) (P=0.208). Patients with NASH were older, had a higher model of end-stage liver disease score and a higher BMI, but patient survival and graft survival were equivalent to other indications. Patients with hepatocellular carcinoma (HCC) as primary indication for liver transplantation showed significantly inferior overall survival as compared with the other indications (P=0.003). Patients with NASH had coexisting HCC in 53.7% of cases, whereas HCC in ALD, HCV and other indications was prevalent in 31.2, 47.7, and 34.5%, respectively (P<0.0001). Patients with NASH had a higher incidence of advanced HCCs (outside the Milan criteria) than patients with ALD, HCV, and other indications (P=0.034). Postoperative complications were significantly higher in the NASH cohort (P=0.048).

CONCLUSION

In this single-center LT database analysis, patients with NASH have a higher incidence and a more rapid progression of HCC as well as an increased incidence of postoperative complications. Our findings warrant confirmation by others.

摘要

背景与目的

非酒精性脂肪性肝炎(NASH)是全球范围内肝移植(LT)日益普遍的适应证。该队列中移植后的相对结局描述较少。我们旨在分析与其他适应证相比,NASH肝移植的发生率和结局。

患者与方法

这是一项对2002年至2012年间在奥地利因斯布鲁克医科大学记录的513例接受已故供体成人肝移植患者的回顾性分析。

结果

以NASH肝硬化作为肝移植适应证的患病率为12.7%(65/513)。NASH患者的生存率与其他适应证相当,包括酒精性肝脂肪变性(ALD)和丙型肝炎病毒(HCV)(P = 0.208)。NASH患者年龄更大,终末期肝病模型评分更高,体重指数更高,但患者生存率和移植物生存率与其他适应证相当。以肝细胞癌(HCC)作为肝移植主要适应证的患者总体生存率明显低于其他适应证(P = 0.003)。53.7%的NASH患者合并HCC,而ALD、HCV和其他适应证中HCC的患病率分别为31.2%、47.7%和34.5%(P < 0.0001)。NASH患者中晚期HCC(超出米兰标准)的发生率高于ALD、HCV和其他适应证的患者(P = 0.034)。NASH队列中的术后并发症明显更高(P = 0.048)。

结论

在这个单中心肝移植数据库分析中,NASH患者HCC的发生率更高、进展更快,术后并发症的发生率也增加。我们的研究结果有待他人证实。

相似文献

1
High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation.非酒精性脂肪性肝炎患者作为尸体肝移植的主要适应证时,肝细胞癌和术后并发症的发生率较高。
Eur J Gastroenterol Hepatol. 2019 Feb;31(2):205-210. doi: 10.1097/MEG.0000000000001270.
2
Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.肝移植术后非酒精性脂肪性肝炎肝硬化的转归:与酒精性肝硬化的比较。
Ann Hepatol. 2019 Nov-Dec;18(6):855-861. doi: 10.1016/j.aohep.2019.06.014. Epub 2019 Sep 6.
3
Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States.非酒精性脂肪性肝炎是美国肝肾联合移植中增长最为迅速的适应症。
Transplantation. 2016 Mar;100(3):607-12. doi: 10.1097/TP.0000000000000945.
4
Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.乙型肝炎病毒相关性肝移植:适应证减少及趋势变化
World J Gastroenterol. 2015 Jul 14;21(26):8140-7. doi: 10.3748/wjg.v21.i26.8140.
5
Poor Survival After Retransplantation in NASH Cirrhosis.非酒精性脂肪性肝炎肝硬化患者再次肝移植后生存率较差。
Transplantation. 2019 Jan;103(1):101-108. doi: 10.1097/TP.0000000000002135.
6
Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes.美国非酒精性脂肪性肝炎的肝移植:时间趋势与结局
Dig Dis Sci. 2017 Oct;62(10):2915-2922. doi: 10.1007/s10620-017-4684-x. Epub 2017 Jul 25.
7
Combination of racial/ethnic and etiology/disease-specific factors is associated with lower survival following liver transplantation in African Americans: an analysis from UNOS/OPTN database.种族/族裔与病因/疾病特异性因素的组合与非裔美国人肝移植后的较低生存率相关:来自器官共享联合网络/器官获取与移植网络数据库的分析
Clin Transplant. 2014 Jul;28(7):755-61. doi: 10.1111/ctr.12374. Epub 2014 May 21.
8
Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC.未来对肝移植的需求趋势:非酒精性脂肪性肝炎和肝细胞癌患者的出生队列效应。
Transplantation. 2019 Jan;103(1):140-148. doi: 10.1097/TP.0000000000002497.
9
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation.非酒精性脂肪性肝病和非酒精性脂肪性肝炎:肝移植的相关影响。
Liver Transpl. 2018 Feb;24(2):166-170. doi: 10.1002/lt.25003.
10
Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.非酒精性脂肪性肝炎肝细胞癌患者接受终末期肝病模型例外情况的比例较低,且移植等待时间较长。
Liver Transpl. 2016 Oct;22(10):1356-66. doi: 10.1002/lt.24507.

引用本文的文献

1
Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review.代谢功能障碍相关脂肪性肝炎相关肝细胞癌的发病机制与管理:一篇叙述性综述
Ewha Med J. 2024 Oct;47(4):e65. doi: 10.12771/emj.2024.e65. Epub 2024 Oct 31.
2
Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma: A systematic review and meta-analysis.非酒精性脂肪性肝炎相关肝细胞癌与非非酒精性脂肪性肝炎病因的肝细胞癌的肝移植:一项系统评价和荟萃分析。
PLoS One. 2025 Mar 19;20(3):e0317730. doi: 10.1371/journal.pone.0317730. eCollection 2025.
3
Evolution of liver transplantation in the metabolic dysfunction-associated steatotic liver disease era: Tracking impact through time.
代谢功能障碍相关脂肪性肝病时代肝移植的演变:随时间追踪影响
World J Transplant. 2024 Dec 18;14(4):98718. doi: 10.5500/wjt.v14.i4.98718.
4
The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies.非酒精性脂肪性肝炎的负担:流行病学研究的系统评价
Gastro Hep Adv. 2022 Jul 19;1(6):1049-1087. doi: 10.1016/j.gastha.2022.06.016. eCollection 2022.
5
Overexpression of wild-type HRAS drives non-alcoholic steatohepatitis to hepatocellular carcinoma in mice.野生型 HRAS 的过表达可导致小鼠非酒精性脂肪性肝炎向肝细胞癌发展。
Zool Res. 2024 May 18;45(3):551-566. doi: 10.24272/j.issn.2095-8137.2024.002.
6
The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients.严重代谢功能障碍相关脂肪性肝病患者肝移植的结局
Biomedicines. 2023 Nov 20;11(11):3096. doi: 10.3390/biomedicines11113096.
7
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.非酒精性脂肪性肝炎相关肝细胞癌:发病机制与治疗。
Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):487-503. doi: 10.1038/s41575-023-00754-7. Epub 2023 Mar 17.
8
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.肝移植后发生的非酒精性脂肪性肝病或非酒精性脂肪性肝炎的代谢机制与治疗。
Nat Rev Endocrinol. 2022 Oct;18(10):638-650. doi: 10.1038/s41574-022-00711-5. Epub 2022 Jul 15.
9
and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation.以及肝移植后代谢功能障碍相关脂肪性肝病的复发。
World J Hepatol. 2021 Dec 27;13(12):1991-2004. doi: 10.4254/wjh.v13.i12.1991.
10
Mechanisms of nonalcoholic fatty liver disease and implications for surgery.非酒精性脂肪性肝病的发病机制及其对手术的影响。
Langenbecks Arch Surg. 2021 Feb;406(1):1-17. doi: 10.1007/s00423-020-01965-1. Epub 2020 Aug 24.